Updated PMCPA Guidance on Clauses 3.1 and 11

The PMPCA has published updated guidance on Clauses 3.1 and 11 which reflects the requirements of the 2024 ABPI Code of Practice. The guidance includes:

• Activities conducted by, and governance for, medical science liaisons (MSLs)
• The legitimate exchange of medical and scientific information during the development of a medicine (LEMs)
• Advance budgetary notification (ABN).

This guidance has been updated from the archived Clause 3 guidance that was previously on the website.

While this guidance focuses on Clauses 3.1 and 11, companies should bear in mind that other clauses of the Code, as well as other laws and regulations might also be relevant. Companies should always consider the overall impression created by their activities, materials etc. In the event of a complaint, each case would be considered on its individual merits.

For any queries on the new guidance, please contact info@pmcpa.org.uk